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Abstract  
Background: The impact of lesion focality and centricity in relation to patient outcome and 1 
disease recurrence of vulvar intraepithelial neoplasia (VIN) is an understudied area of 2 
research, especially in immunocompromised women. The prevalence and incidence of VIN 3 
have increased steadily since the 1980s, because of the co-existence of human papilloma 4 
virus (HPV) and human immunodeficiency virus (HIV). In this study, we have retrospectively 5 
examined the records of VIN patients (both HIV+ and HIV-) to determine the effect of lesion 6 
focality and centricity with respect to the risk of and interval to disease recurrence. 7 
Material & Methods: All women diagnosed with VIN and managed between January 2002 8 
and December 2011 were included and followed up until December 2017. They were 9 
identified by searching histopathology and diagnosis records in hospital colposcopy 10 
databases. Symptoms at the time of presentation, subsequent treatment and outcomes 11 
were collated, including the influences of multifocality and multicentricity on time to disease 12 
recurrence. 13 
Results: A total of 90 women with were VIN identified, from which 78 records were 14 
recovered indicating focality and centricity. 15 patients were HIV+ and 75 were HIV-. HIV+ 15 
women presented with fewer symptoms than the HIV- women.  Multicentricity caused a 16 
more rapid recurrence of disease than unicentricity (p=0.006), whereas multifocality 17 
increased the risk of recurrence more than unifocality (p<0.0001). Viral load in the HIV+ 18 
patients was not associated with time to disease recurrence but the number of CD4+ 19 
lymphocytes present in HIV+ patients was.  20 
Conclusion: Both focality and centricity have an effect on interval to recurrence and final 21 
patient outcome, with multifocal disease having a poorer prognosis. Centricity and focality 22 
should be recorded at the time of diagnosis and act as a concern  for disease recurrence. 23 
HIV+ VIN patients with multifocal disease and/or known immunosuppression (low CD4+ 24 
l pho te ou ts  should e regarded as high-risk  patie ts a d treated a ordi gl . 25 
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Introduction 
Vulval intraepithelial neoplasia (VIN) is a condition in which changes occur in the skin 40 
covering the vulva of female external genitalia. It can change from a condition that is 41 
relatively benign (VIN1) into one that has the potential to become invasive (VIN3), affecting 42 
all surface tissues of the pelvic floor (mons into perianal region). In 1986, the International 43 
So iet  for the Stud  of Vul o agi al Disease ISSVD  de ised a lassifi atio  s ste  for VIN, 44 
which was updated in 2004 and remains the most commonly used system in literature [1]. 45 
Pre-invasive abnormalities in vulval tissue are categorised as VIN 1–3, depending on the 46 
level of dysplasia present, which is similar to the current grading of cervical intraepithelial 47 
neoplasia (CIN), a related and often coincident (multicentric) finding during clinical 48 
examination and diagnosis. It is widely believed that VIN 1 has a low malignant potential and 49 
is not a precursor of VIN 2 or 3, which have high malignant potential, often presenting with 50 
or developing into invasive squamous cell carcinoma (SCC).  51 
 
Since the 1980s, the incidence of VIN as a disease entity has been reported to have 52 
increased in several countries and in particular within the younger female population [2]. 53 
Even so, VIN remains a relatively uncommon condition, with an unclear aetiology. Younger 54 
o e  te d to ha e the usual-t pe  VIN that is characterized by previous or existing 55 
e posure to hu a  papillo a irus HPV , hereas older o e  te d to ha e the u usual-56 
t pe  VIN (also called differentiated VIN), which is not related to HPV exposure, but is related 57 
to chronic dermatological conditions, in particular vulval lichen sclerosis [3]. The symptoms 58 
reported by patients with VIN are itching, burning, dyspareunia and the appearance of 59 
leucoplakic patches in any part of the vulva.  Often patients are asymptomatic as well and 60 
suspected VIN is observed during colposcopy for cervical abnormality or during general 61 
gynaecological examination. Emerging evidence suggest that the type of VIN and recurrence 62 
of disease may be related to the presence of viruses other than HPV, such as human 63 
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immunodeficiency virus (HIV) and in immunocompromised patients, suggesting that 64 
immunomodulation may have a prognostic effect in some, but not all, forms of VIN [4].  65 
 
Due to the multi-factorial and heterogeneous nature of VIN, there is no single characteristic 66 
or pathognomonic feature that can facilitate the diagnosis of VIN. If VIN is suspected, visual 67 
inspection of the vulva and surrounding tissues (cervix, vagina, perineum, anus, rectum and 68 
gluteal folds) with vulvoscopy guiding the collection of  vulval biopsy and confirmation of the 69 
disease is made by histological examination. VIN in more than one part of the vulval tissue is 70 
defined as multifocal, whilst the presence of lesions in more than one genital site is defined 71 
as being multicentric disease. The importance of vulvoscopy is based on the observed 72 
prevalence of microscopic abnormalities adjacent to the gross lesion that becomes 73 
pronounced with the uptake of acetic acid. In some series, additional areas of VIN have been 74 
found in 80% of the areas adjacent to the primary lesion [5]. This high rate of concurrent 75 
disease is most characteristic of younger women. 76 
 
There are numerous standard treatments for VIN and for the prevention of VIN2/3 77 
progressing to vulval cancer [6-9]. The gold standard treatment for high-grade vulval 78 
intraepithelial lesions is surgery, either localized or radical excision or laser ablation [10]. 79 
Alternatively, immune modulators such as imiquimod [11-13] can be used as adjunctive 80 
therapy, although the efficacy and side effects of this combined treatment remain 81 
undetermined.  82 
 
The primary aim of this study was to determine the impact of lesion focality and centricity at 83 
VIN presentation in relation to patient outcome and disease recurrence. In particular, the 84 
effectiveness of different treatment modalities on disease free duration, disease recurrence, 85 
and failure rates, based on focality and centricity of the disease at presentation was 86 
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assessed. In addition, this study also assesses how VIN presentation and outcomes varied 87 
with immune status, specifically HIV status was used to interrogate this.  88 
 
Methods 89 
 
This retrospective cohort study was conducted over 10 years in a tertiary University Hospital 90 
setting (the West London Cancer Centre, Imperial College Hospitals NHS Trust) by examining 91 
the re ords of o e  at Ha ers ith a d St Mar s Hospitals et ee  January 2002 and 92 
December 2011. The women were identified through a search of histopathology and 93 
colposcopy databases. All women diagnosed with VIN and managed within this period were 94 
included; women were suitable for inclusion irrespective of VIN type or grade of the disease. 95 
A search by histological diagnosis of VIN was performed and hospital numbers obtained.  St. 96 
Mary s Hospital data was collected from the colposcopy database Excelicare  and pathology 97 
database Telepath . Hammersmith Hospital data was obtained from patients  paper medical 98 
and histopathology records.  99 
 
Symptoms at the time of presentation were collated, together with patient age at the time 100 
of initial presentation, smoking status, HPV and HIV status, CD4+ lymphocyte count and viral 101 
load (only in the HIV+ patients), and if the lesions present were unifocal/multifocal and 102 
unicentric/multicentric. Viral load was determined using an immunoassay (IA) that 103 
simultaneously detects both antibody to human immunodeficiency virus (HIV) and HIV p24 104 
antigen (Architect HIV Ag/Ab Combo) and confirmation was made using LIAISON® XL MUREX 105 
HIV Ab/Ag HT. CD4 positivity was determined using fluorescence activated cell sorting on a 106 
BD FACS Canto analyser (BD Biosciences, San Jose, CA).  The initial, subsequent and 107 
adjunctive treatment regimen(s), whether the patient remained disease free or if disease 108 
recurred (until December 2017), the time from treatment to recurrence and final patient 109 
outcome(s) were all recorded. 110 
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Univariate analysis using permutation 2 tests (10 000 permutations; R version 2.10) were 111 
used to evaluate statistical significance with respect to the effect of treatment on VIN 112 
recurrence and patient outcomes, hilst Fisher s e a t test a d li ear regressio  a al sis 113 
(GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla California USA, 114 
www.graphpad.com) were used to determine the influences of multifocality and 115 
multicentricity on time to disease recurrence after treatment.  Demographic data were 116 
analyzed with unpaired Stude t s t-test ith Wel h s orre tio  for o -uniform variances 117 
(Prism version 7.00).  118 
 
Results 119 
 
A total of 90 women with a diagnosis of VIN were identified during the 10 years study 120 
period. The mean (± SD) age at presentation was 44.8 ± 15.1 years (range 20-86) for the 121 
patient cohort. Of these, 15 patients (16.6%) were HIV+ and 75 (83.3%) were HIV-. The ages 122 
of these two groups at presentation were not significantly different (40.4 ± 8.8 years (range 123 
27-57) and 45.7 ± 15.9 (range 20-86) respectively, (p=0.313). 124 
 
At the time of presentation, 61% of the HIV- patients were smokers whilst only 23% of the 125 
HIV+ patients were smokers – probably should put total numbers in brackets, alongside 126 
percentages.  Although those who smoked in the HIV+ group smoked less than 20 127 
cigarettes/day and  some of the HIV- group  - insert number in brackets(6%) smoked more 128 
than 20 cigarettes/day, analysis showed that smoking was not a confounding factor in later 129 
analyses for either group. 130 
 
The HIV+ subgroup presented with fewer symptoms than the HIV- group, and more patients 131 
were asymptomatic (Figure 1a). The presence of a lesion, pruritus, pain or a combination of 132 
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these symptoms were similar in both groups, although sore ess  as o l  reported i  the 133 
HIV- group. The type of lesion present and initially diagnosed was similar in both groups, 134 
with 76% of the HIV- group and 93% of the HIV+ group, respectively presenting with VIN3 or 135 
invasive disease (Figure 1b). Furthermore, 60% of HIV+ patients had a coincidental diagnosis 136 
of cervical intraepithelial neoplasia (CIN) and or vaginal intraepithelial neoplasia (VAIN), in 137 
contrast to only 28% of HIV- patients (Figure 1c). The majority HIV+ patients (87%) had a 138 
previous diagnosis of CIN/VAIN, compared to only 48% of the HIV- patients (Figure 1c). – 139 
insert numbers as well as percentagesThis data was not statistically significantly different 140 
p= . ; Fisher s e a t test . 141 
 
Histological diagnosis confirmed the presence of VIN in all patients, with 24 women (37%) 142 
having unifocal disease and 54 (69%) having multifocal disease. Furthermore, 30 patients 143 
(38%) had unicentric disease and 48 (61%) had multicentric disease (Table 1) and in 12 cases 144 
(15%), the number and positions of lesions were not recorded. Since multiple combinations 145 
are possible at diagnosis, these possible combinations are presented together in Table 1.  146 
 
There were nine different management plans put in place at initial presentation (Table 2) 147 
and none of the patients were treated with cidofovir or photodynamic therapy; 39 patients 148 
were managed conservatively. Of this group, one went on to have examination under 149 
anaesthesia (EUA) and one went on to develop invasive disease. Laser treatment as initial 150 
treatment was used on 23 patients and of these, 7 had recurrent disease within a year and 151 
15 within 2 years. Diathermy ablation was used to treat 12 patients and 3 patients had 152 
diathermy excision. Only one patient in our cohort who was treated with imiquimod alone, 153 
relapsed and had recurrence of disease – could define time in this as only one patient. In this 154 
case, the patient did not require any further treatment (Table 2). One patient had 155 
radiotherapy (following diagnosis of invasive cancer), one referred to a cancer centre and 1 156 
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had a vulvectomy. At the time of writing, only 3 (20%) HIV+ patients and 30 (38.5%) HIV- 157 
patients are disease free, whilst 12 patients (13.3%) have been lost to follow-up.  One 158 
patie t died of Hodgki s l pho a a d 3 died of auses that were not recorded in their 159 
notes and two developed invasive vulval carcinoma (Table 2). Of the 78 patients that had 160 
detailed notes available, 12 out of the 15 HIV+ group (80%) and 30 out of the 63 remaining 161 
HIV- patients (47.6%) went on to have recurrent disease (Figure 2).  162 
 
An analysis of the effect of centricity and focality on the time to disease recurrence indicated 163 
that both factors had a significant effect on the rate of recurrence; multicentricity was more 164 
rapid than u i e tri it  p= . ; Fisher s e a t test  a d ultifo alit  as ore rapid than 165 
u ifo alit  p< . , Fisher s e a t test  Ta le ) in relation to disease recurrence and 166 
progression. A total of 31 patients presented with multifocal and multicentric disease and 23 167 
presented with multifocal and unicentric disease. These multifocal-multicentricpatients had 168 
a significantly (p=0.0005) shorter time to disease recurrence (Table 1).  The average time to 169 
disease recurrence in HIV+ patients was 3.2 years, compared to 5.4 years in the HIV- 170 
patients, with 73% of the HIV+ patients presenting with multifocal disease compared to only 171 
61% of the HIV- patients.  172 
 
In order to dissect the cause of the accelerated disease recurrence in HIV+ patients, CD4+ 173 
lymphyocyte counts and viral load were examined. The data showed a significant positive 174 
correlation between CD4+ lymphocyte count at diagnosis and time to recurrence (Figure 3a). 175 
By contrast, no significant relationship between viral load (at time of diagnosis or at time of 176 
disease?) and time to recurrence of VIN could be observed (Figure 3b). The slope of the line 177 
for CD4+ lymphocyte count and time to recurrence was 0.0039 years per CD4+ lymphocyte 178 
cell identified. This provides an estimate of time to disease recurrence in the HIV+ patient 179 
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population based on initial CD4+ lymphocyte counts, e.g. 1000 CD4+ cells predicts a 3.9 year 180 
delay in disease recurrence.  181 
 
182 
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Discussion 183 
 
The data presented here shows that both focality and centricity of disease at initial diagnosis 184 
have a statistically significant effect on both interval to recurrence and final outcome for the 185 
patient diagnosed with VIN. Recurrence within 1 year was highest overall in those with 186 
multifocal/multicentric disease and also 6 patients (7%) of this cohort developing invasive 187 
forms of vulval cancer. This has been reported previously in only a small set of studies [14-188 
18]. 189 
 
The majority of women presented with VIN 2/3, and the main concern with VIN 2/3 is its 190 
pote tial to progress to a er of the ul a. A o a s risk of de elopi g a er of the 191 
vulva by the age of 75 years varies between countries, and ranges from 0.01% to 0.28% 192 
although the true rate of progression to invasive vulval cancer in women with untreated 193 
high-grade VIN is debatable, with some studies suggesting a rate as high as 9% [19]. The 194 
rates and the risk of progression in treated lesions has been reported as between 2% and 5% 195 
[2], with an increase in vulval cancer in women under the age of 50 years being increasingly 196 
documented [6, 20]. This has been linked to an increasing incidence of VIN in younger 197 
women, which has been attributed to infection with HPV, smoking or poor immunological 198 
status especially in HIV+ women [4, 14, 21]. Treatment modality did not seem to have any 199 
significant effect on outcome. This is similar to previous studies where radical vulvectomy or 200 
combination therapy had no significant effect on patient outcomes [7, 8, 22]. What is clear 201 
from previous work is that immunocompromised patients are at a higher risk of recurrent 202 
disease [23].  203 
In this study, 17% of the patient group were HIV+, which is significantly higher when 204 
compared to the general female population of West London aged 21-86, during the 205 
diagnostic period, where 0.1% were known to be HIV+. This suggests that VIN may occur as a 206 
consequence of HIV infection, possibly through the loss of CD4+ lymphocytes or increased 207 
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viral load. The corollary of this would be that patients that have increased viral loads or were 208 
HIV+ at the time of initial presentation might have a greater susceptibility to disease 209 
recurrence. These ideas were examined and viral load did not seem to have any effect on 210 
the rate of disease recurrence, but CD4+ lymphocyte count did in our patient cohort. In fact, 211 
the data (albeit from a small sample) suggests that CD4+ count could be a good predictor of 212 
disease recurrence in HIV+ women with VIN, although these data need confirmation in a 213 
larger sample for any useful prognostic value. 214 
 
Symptoms at presentation were very similar in both HIV+ and HIV- patients, with 60% 215 
presenting with a lesion alone or alongside other symptoms including pruritus and vulval 216 
pain. We noted a greater number of HIV+ patients (93%) had the more advanced form of 217 
VIN (VIN3) when compared to only 76% of the HIV- patients, suggesting that the presumably 218 
higher CD4+ lymphocyte count in the HIV- patients provides suitable immune surveillance 219 
and prevention of conversion to malignancy – I WOULD PROBABLY SAY THIS MAY HAVE 220 
PREVENTED PROGRESSION TO HIGHER GRADE DISEASE, RATHER THAN CONVERSION TO 221 
MALIGNANCY. This is supported by the observation that the majority (85%) of HIV+ patients 222 
had a synchronous or previous diagnosis of CIN/VAIN, whilst synchronous or metachronous 223 
CIN/VAIN were only diagnosed in <50% of HIV- patients. These data suggest that HIV+ 224 
patients have a greater propensity for the development of such neoplasms. Radical 225 
vulvectomy did not seem to show any improvement over any other treatment modality 226 
suggesting that a conservative approach in younger women is an acceptable treatment 227 
option. 228 
 
Conclusions 229 
 
The centricity and focality of VIN lesions at the time of diagnosis should be determined and 230 
the presence of both parameters act as a warning for the gynaecologist/ gynaecology 231 
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oncologist to initiate close monitoring for disease recurrence. We believe that the presence 232 
of both parameters may eventually be used to predict those women at high risk of VIN 233 
recurrence and progression, which may influence and guide treatment choices. 234 
 
Immunosuppressed groups, in particular HIV+ patients, are more likely to present with 235 
multifocal and more advanced disease (VIN2/3), and as such HIV+ patients with multifocal 236 
VIN and/or known immunosuppression (demonstrated by a low CD4+ lymphocyte count) 237 
should e regarded as high-risk  patie ts a d treated a ordi gl . Su h groups a  e 238 
appropriately managed in clinics with access to multi-disciplinary services, including 239 
dermatologists, whose experience with the use of imiquImod (or other treatment 240 
modalities) may change the treatment choice. 241 
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Table 1: Interval to VIN disease recurrence based on focality and centricity  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fisher s e a t test i di ated that ulti e tri  disease sig ifi a tl  shorte ed the i ter al to 
disease recurrence (p=0.0063) and multifocal disease significantly shortened the interval to 
disease recurrence (p<0.0001) when compared to their unicentric or unifocal counterparts. 
The permutation 2 p-value for the comparison of multifocal and multicentric disease versus 
multifocal and unicentric disease is also shown. 
 
 
 
 
Lesion type  
 
Interval to Recurrence (Years) 
Totals 
<1 2  3-5 >5  
Unifocal and unicentric 
 
1 2 2 2 7 
Unifocal and multicentric 
 
14 2 0 1 17 
Multifocal and unicentric 
 
3 10 4 6 23 
Multifocal and multicentric 11 10 4 6 31 
Totals 29 24 10 15 
78 
Permutation 2 p-value 0.0005 
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Table 2: The effect of treatment modality on the interval to recurrence and final patient outcome in December 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Follow up means a patient with chronic VIN, but no progression of disease and so on long-term observation only; Re-treatment/EUA means a different 
treatment modality was applied either after evaluation under anaesthesia (EUA) or independent of re-diagnosis, invasive means VIN had progressed to 
vulval cancer. 
Treatment 
Interval from treatment to recurrence (years) 
Totals 
Final Outcome* 
Totals ≤   1-2  3-5  >5  Follow up Re-treated/EUA Invasive Died 
 None 1 2 3 0 6 6 0 0 0 6 
 Observation 17 8 1 4 30 31 1 1 0 33 
 Laser  7 8 3 5 23 13 9 1 3 26 
 Diathermy ablation 3 4 2 3 12 6 6 0 0 12 
 Diathermy excision 0 1 1 1 3 0 2 0 1 3 
 Imiquimod 0 1 0 0 1 1 0 0 0 1 
 Radiotherapy 0 0 0 1 1 0 1 0 0 1 
 Referral to cancer centre 1 0 0 0 1 0 1 0 0 1 
 Vulvectomy 0 0 0 1 1 0 1 0 0 1 
Totals 29 24 10 15 78 57 21 2 4 84 
Permutation 2 p-value 0.14 0.12 
16 
 
References:  
 
1. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar 
intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. 
J Reprod Med. 2005 Nov;50(11):807-10. PubMed PMID: 16419625. English. 
 
2. Jones RW. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol 
Oncol. 2001;22(6):393-402. PubMed PMID: 11874067. English. 
 
3. van der Avoort IAMMDMS, Shirango HMD, Hoevenaars BMMD, Grefte JMMMDPD, 
de Hullu JAMDPD, de Wilde PCMMDPD, et al. Vulvar Squamous Cell Carcinoma is a 
Multifactorial Disease Following Two Separate and Independent Pathways. International 
Journal of Gynecological Pathology. 2006;25(1):22-9. English. 
 
4. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV 
coinfection and the risk of neoplasias of the lower genital tract: a review of recent 
developments. CMAJ. 2003;169(5):431-4. English. 
 
5. Bernstein SG, Kovacs BR, Townsend DE, Morrow CP. Vulvar carcinoma in situ. Obstet 
Gynecol. 1983 Mar;61(3):304-7. PubMed PMID: 6823372. English. 
 
6. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the 
influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997 Sep;90(3):448-52. 
PubMed PMID: 9277660. English. 
 
7. Joura EA. Epidemiology, diagnosis and treatment of vulvar intraepithelial 
neoplasia. Curr Opin Obstet Gynecol 2002;14(39-43). 
 
8. Todd RW, Luesley DM. Medical management of vulvar intraepithelial neoplasia. J. 
2005 Oct;9(4):206-12. PubMed PMID: 16205189. English. 
 
9. Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C. Evaluation of different 
treatment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, 
photodynamic therapy, excision and vulvectomy. Gynecol Oncol. 2006;100:271-5. 
 
10. Hillemanns P, Untch M, Dannecker C, Baumgartner R, Stepp H, Diebold J, et al. 
Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J 
Cancer. 2000 Mar 01;85(5):649-53. PubMed PMID: 10699944. English. 
 
11. Le T, Menard C, Hicks-Boucher W, Hopkins L, Weberpals J, Fung-Kee-Fung M. Final 
results of a phase 2 study using continuous 5% Imiquimod cream application in the primary 
treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol. 2007 
Sep;106(3):579-84. PubMed PMID: 17582474. English. 
 
12. Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar 
intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol. 2007 
Nov;107(2):219-22. PubMed PMID: 17655918. English. 
 
13. Tristram A, Fiander A. Clinical responses to Cidofovir applied topically to women 
with high grade vulval intraepithelial neoplasia. Gynecol Oncol. 2005 Dec;99(3):652-5. 
PubMed PMID: 16169066. English. 
17 
 
 
14. Bradbury M, Cabrera S, Garcia-Jimenez A, Franco-Camps S, Sanchez-Iglesias JL, Diaz-
Feijoo B, et al. Vulvar intraepithelial neoplasia: clinical presentation, management and 
outcomes in women infected with HIV. AIDS. 2016;30(6):859-68. English. 
 
15. Nathan LM. Vulvovaginal disorders in the elderly woman. Clinical Obstetrics & 
Gynecology. 1996;39(4):933-45. English. 
 
16. Rettenmaier MAM, Berman MLM, DiSaia PJM. Skinning vulvectomy for the 
treatment of multifocal vulvar intraepithelial neoplasia. Obstet Gynecol. 1987;69(2):247-50. 
English. 
 
17. Stephenson RDDO, Denehy TRMD. Rapid spontaneous regression of acute-onset 
vulvar intraepithelial neoplasia 3 in young women: A case series. J Low Genit Tract Dis. 
2012;16(1):56-8. English. 
 
18. van Beurden M, ten Kate FJ, Smits HL, Berkhout RJ, de Craen AJ, van der Vange N, et 
al. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract 
neoplasia is associated with transcriptionally active human papillomavirus. Cancer. 1995 Jun 
15;75(12):2879-84. PubMed PMID: 7773937. English. 
 
19. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal 
vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med. 2002 
Sep;47(9):701-5. PubMed PMID: 12380448. English. 
 
20. Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar 
neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell 
carcinoma of the vulva in young women. J Reprod Med. 2000 Aug;45(8):613-5. PubMed 
PMID: 10986677. English. 
 
21. Jones RWFF, Rowan DMF, Stewart AWBD. Vulvar Intraepithelial Neoplasia: Aspects 
of the Natural History and Outcome in 405 Women. Obstet Gynecol. 2005;106(6):1319-26. 
English. 
 
22. Hockel M, Dornhofer N. Vulvovaginal reconstruction for neoplastic disease. Lancet 
Oncol. 2008 Jun;9(6):559-68. PubMed PMID: 18510987. English. 
 
23. Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting high-grade vulvar 
intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to 
different HPV types occurring in immunocompromised patients. Am J Surg Pathol. 2013 
Jan;37(1):53-60. PubMed PMID: 23026935. English. 
 
 
18 
 
Figure Legends 
Figure 1. The effect of HIV status on symptoms at the time of presentation, the type of 
lesion present and presence of co-morbidities. 
Panel a shows the symptoms described by HIV- patients (upper pie chart) and those 
described by HIV+ patients at the time of initial presentation. The numbers under each pie 
chart indicate the numbers of HIV- and HIV+ patients. The percentages are values for each 
patient group. Panel b shows the effect of HIV status on lesion type diagnosed at initial 
presentation. Visual methods and histological confirmation were used to diagnose lesion 
type and related to previous diagnosed HIV status. Microinvasive/invasive indicate the 
presence of vulval cancer. Panel c shows whether diagnosis of CIN or VAIN or both were 
present prior to initial diagnosis of VIN or were coincidental findings on the day of initial 
diagnosis. Data are presented as the % of the entire patient cohort based on HIV status. 
 
Figure 2. The effect of HIV status on recurrence of VIN at any time after treatment.  
Differential diagnosis of VIN recurrence within the period January 2002 to December 2017 
(as reported by the consultant histopathologist) was recorded.  Data are presented as the % 
of the entire patient cohort. 
 
 
Figure 3. The effect of viral load and CD4+ lymphocyte count on the time to VIN recurrence 
in HIV+ patients.  
Panel a shows the effect of viral load measured by an immunoassay (IA) that simultaneously 
detects both antibody to human immunodeficiency virus (HIV) and HIV p24 antigen 
(Architect HIV Ag/Ab Combo) and confirmation using LIAISON® XL MUREX HIV Ab/Ag HT, at 
the time of VIN recurrence. The time to recurrence was measured as the calendar year from 
initial diagnosis to report of a new lesion. CD4+ lymphocyte counts were measured using 
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fluorescence activated cell sorting and is presented as number of CD4+ lymphocytes per 109 
cells. Linear regression was used to calculate potential relationships between viral load (n=7) 
and CD4+ lymphocyte count (n=7) and time to recurrence. Data are not shown when 
encompassed by another symbol. Pearson correlation co-efficient and p-values were 
calculated using Prism version 7.00 software. 
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